Daiken Biomedical Co., Ltd. (TPE:7780)
Taiwan · Delayed Price · Currency is TWD 16.55
+0.40 (2.48%)
At close: Oct 8, 2026
Daiken Biomedical Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| 13,332 | 14,540 | 10,860 | - | - | |
Market Cap Growth | 17.25% | 33.88% | - | - | - |
Enterprise Value | 8,188 | 9,496 | 9,874 | - | - |
Last Close Price | 16.55 | 17.00 | 16.42 | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
PE Ratio | 30.06 | 43.03 | 101.90 | - | - |
Forward PE | - | 34.13 | - | - | - |
PS Ratio | 6.10 | 7.67 | 7.97 | - | - |
PB Ratio | 2.74 | 2.67 | 8.31 | - | - |
P/TBV Ratio | 2.74 | 2.67 | 8.33 | - | - |
P/FCF Ratio | 50.91 | 53.42 | 215.06 | - | - |
P/OCF Ratio | 50.77 | 53.34 | 209.86 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
EV/Sales Ratio | 3.75 | 5.01 | 7.25 | - | - |
EV/EBITDA Ratio | 20.24 | 32.17 | 64.48 | - | - |
EV/EBIT Ratio | 20.79 | 32.95 | 66.31 | - | - |
EV/FCF Ratio | 31.26 | 34.89 | 195.53 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Debt / Equity Ratio | 0.02 | 0.02 | 0.00 | 1.12 | 0.60 |
Debt / EBITDA Ratio | 0.29 | 0.40 | 0.01 | 1.35 | 1.21 |
Debt / FCF Ratio | 0.45 | 0.44 | 0.05 | 2.63 | 3.27 |
Net Debt / Equity Ratio | -1.06 | -0.39 | -0.87 | -0.04 | -0.47 |
Net Debt / EBITDA Ratio | -12.83 | -7.17 | -7.43 | -0.05 | -0.96 |
Net Debt / FCF Ratio | -19.64 | -7.78 | -22.52 | -0.10 | -2.59 |
Asset Turnover | 0.56 | 0.51 | 1.19 | 1.87 | - |
Inventory Turnover | 1.95 | 2.08 | 1.99 | 1.71 | - |
Quick Ratio | 4.29 | 5.33 | 5.36 | 0.80 | 1.23 |
Current Ratio | 4.75 | 13.12 | 6.56 | 1.64 | 2.17 |
Return on Equity (ROE) | 14.21% | 10.01% | 13.71% | 67.55% | - |
Return on Assets (ROA) | 6.26% | 4.83% | 8.15% | 20.01% | - |
Return on Invested Capital (ROIC) | - | 13.35% | 55.95% | 94.00% | 77.31% |
Return on Capital Employed (ROCE) | 8.00% | 5.30% | 11.40% | 68.80% | 38.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Earnings Yield | 3.19% | 2.32% | 0.98% | - | - |
FCF Yield | 1.96% | 1.87% | 0.46% | - | - |
Dividend Yield | 4.22% | 4.11% | 2.46% | - | - |
Payout Ratio | 128.54% | 174.40% | 2.89% | 87.59% | - |
Buyback Yield / Dilution | -28.50% | -52.12% | -95.20% | -44.34% | - |
Total Shareholder Return | -24.28% | -48.01% | -92.74% | -44.34% | - |